Open access peer-reviewed chapter

Impact of Chronic Medical and Neuropsychiatric Illnesses on Quality of Life and Life Expectancy among Patients at the University of Port Harcourt Teaching Hospital (UPTH)

Written By

Aborlo Kennedy Nkporbu

Submitted: 17 October 2018 Reviewed: 04 December 2019 Published: 06 April 2020

DOI: 10.5772/intechopen.90756

From the Edited Volume

Aging - Life Span and Life Expectancy

Edited by Robert J. Reynolds and Steven M. Day

Chapter metrics overview

787 Chapter Downloads

View Full Metrics

Abstract

The prevalence of chronic medical and psychiatric diseases has continued to increase worldwide, and their consequences have remained a growing concern. Acting with a number of sociodemographic and clinical variables, they tend to affect quality of life (QOL) and onward to life expectancy. There is a direct relationship between QOL and life expectancy. Hypertension and diabetes mellitus acting with adverse environmental factors reset and overamplify the sympathetic outflow, and this may worsen hypertension and or cause depression, dysthymia, and anxiety disorders. Tuberculosis and HIV are two chronic infective medical conditions that equally negatively affect quality of life well-being and life expectancy. These chronic medical and psychiatric conditions have been associated with reduced QOL and life expectancy. The aim of this study, therefore, was to determine the impact of chronic medical and psychiatric disorders (HIV, tuberculosis, diabetes mellitus, hypertension, dysthymia, and GAD) on quality of life and life expectancy. Following ethical approval and informed consent from the participants, 40 subjects from each group of HIV, tuberculosis, diabetes mellitus, hypertension, anxiety, and dysthymia were studied using sociodemographic/clinical questionnaire and the WHOQOL-Bref. The data were analyzed using the SPSS version 20 statistical package. Confidence interval was set at 95% while P-value of less than 0.05 was considered statistically significant. There was reduced QOL on physical, psychological, and social relationship, environment domains, and general health facet, respectively. Chronic medical and psychiatric conditions may contribute to reduced QOL and life expectancy. Management of patients with these conditions should necessarily include attention to their QOL and well-being.

Keywords

  • chronic medical and psychiatric diseases
  • QOL
  • life expectancy
  • UPTH

1. Introduction

The prevalence of chronic medical and psychiatric diseases has continued to increase worldwide, and their consequences have remained a growing concern. Acting with a number of sociodemographic and clinical variables, they tend to negatively affect life expectancy through, among many other pathways, reducing quality of life. Despite healthcare improvements, there has been little evidence of benefit on life expectancy in people with chronic medical and mental disorders [1, 2, 3].

A number of sociodemographic and clinical variables may however serve as key determinants of quality of life and life expectancy. In Nigeria, these medical conditions have remained on the rise [4, 5, 6, 7, 8, 9]. Studies have noted a prevalence of 10–15% for diabetes mellitus and 4.6% for HIV infection [4, 5, 6]. Worldwide, it was estimated that diabetes affected 285 million adults (20–79 years) in 2010, and this figure would likely increase to about 439 million adults by 2030 [6]. The World Health Organization (WHO) has also estimated that 2 billion people, almost a third of the world’s population, have latent TB [7, 8, 9] which is one of the leading causes of mortality worldwide [9, 10, 11]. About 8 million people develop tuberculosis every year, and out of this number, some 3 million die of it, and over 95% are from developing countries [9, 10, 11].

The global prevalence of high blood pressures has been estimated to be between 10 and 15% of adult populations [12], which is also in line with the findings in Africa [13]. However, other studies have reported a worldwide prevalence of 15–30% in adults [14]. The prevalence of hypertension has increased from 11.2% in 1990 to 27.9% in 2010 in rural communities in the Niger Delta and 44.3% in urban Lagos [15, 16, 17]. Over 36 million people have contracted HIV infection worldwide, and over 16 million people are said to have died from the disease [4, 11]. The prevalence of cancer diseases, schizophrenia, and dementia have all continued to increase [18, 19, 20, 21].

In terms of mode of acquisition, while hypertension, diabetes mellitus, cancer, schizophrenia, and dementia have a clear genetic component, in addition to adverse environmental factors [22, 23], HIV and tuberculosis are mainly acquired infections [24, 25, 26]. Furthermore, HIV infection, tuberculosis, and schizophrenia are associated with a high level of stigma and social discrimination [26, 27, 28, 29], another strong determinant of the degree of psychological impact of these chronic conditions. It is also worthy of note that while severe emotional trauma can directly cause hypertension, diabetes, and schizophrenia [30, 31, 32], it can only predispose an individual to acquiring HIV due to poor sense of judgment, leading to sexual indiscretion and other risk-bearing practices [24, 25, 26]. In their late stages, HIV and tuberculosis infections can also cause dementia and mental disorders including schizophrenia-like illnesses [33, 34, 35, 36, 37].

The choice for their comparison was basically borne out of the observation that they all share some common features in terms of chronicity, with subsequent need for long-term medications, direct or indirect effects on the central nervous system (CNS) [25], high rate of mortality [18, 19, 20, 21] and morbidity [32, 33, 34, 35, 36, 37, 38], and impact on emotion [33, 34, 35, 36, 37, 38]. In addition, patients with these conditions need extensive education, attitudinal change, and coping and healthy lifestyle including diet and exercise [39, 40, 41, 42]. The illnesses are equally similar in terms of complications in the central nervous system [21, 23]. Diabetic ketoacidosis, HIV and hypertensive encephalopathies, CNS disseminated tuberculosis, some metastasis to the brain cells, as well as the direct CNS impairment may all directly or indirectly affect the brain cell functions and cognitive ability. This in turn may cause altered sensorium, neuro-affections, neuro-deficits, cognitive impairment, and seizures in some cases. Furthermore, all conditions can directly alter neurotransmitter levels due to direct toxic effects on the brain cells (neurons) either from the viral cells or other opportunistic infections, disseminated tuberculosis to the CNS, hypertensive encephalopathy, or ketoacidotic complication, significantly disrupting relevant neurotransmissions. This may affect particularly the limbic apparatus, the center that regulates mood and controls emotions, anger, and rage.

It is equally important to note that baseline adverse psychosocial factors or psychological distress have been implicated as predictors of schizophrenia, hypertension and diabetes, or HIV infection [9, 10, 11, 12, 43], through impairment of judgment in the later [24, 25, 26]. Also, certain environmental as well as socioeconomic factors have been identified to predispose to tuberculosis like living in an overcrowded environment [9, 10, 11, 12, 43].

Studies have indicated that life expectancy decreases with each additional chronic condition [1, 2, 3]. A study remarked that a 67-year-old person will live on average 22.6 additional years in the absence of any chronic conditions while a 67-year-old person will live 7.7 fewer years and 17.6 fewer years with 5 chronic conditions and ≥10 chronic conditions, respectively [44]. The same study found that the average marginal decline in life expectancy was 1.8 years with each additional chronic condition ranging from 0.4 fewer years with the first condition to 2.6 fewer years with the sixth condition. These results are consistent by sex and race [44].

Another study using a sample of Medicare beneficiaries enrolled as of January 2008, of 21 different chronic conditions and about 1.4 million persons aged 67 and above, found that, on average, a 75-year-old American woman who has no chronic conditions will live 17.3 additional years to more than 92 years old [45]. Conversely, similar individual with five chronic conditions will live, on average, only to age 87, while an individual with 10 or more chronic conditions will survive only to age 80 [45]. Women tend to live longer than men, while white people live longer than black. Clearly, the nature and number of the chronic diseases are important for life expectancy. An individual with heart disease at age 67 is estimated to live an additional 21.2 years on average, while someone of the same age diagnosed with Alzheimer’s disease is only expected to live 12 additional years [46]. Different medical conditions have different life expectancy, but this difference gradually decreases with age and more comorbid conditions [44, 45, 46, 47, 48, 49].

Struggling with multiple chronic illnesses shortens life expectancy dramatically [45, 46, 47, 48, 49], and for older individuals, chronic or multiple chronic conditions equally threaten to reverse recent gains in average life spans. The medical advances and new technologies that have allowed sick people to live longer may not be able to keep up with the growing burden of chronic diseases. It is becoming very clear that preventing the development of additional chronic conditions and giving adequate treatment when they occur in the middle ages and the elderly could be the only way to continue to improve life expectancy. Violence and adverse childhood events are said to speed up aging, and life span continues to increase with each generation.

Concerns about premature mortality among people with chronic mental and medical disorders have been increasing [1, 2, 3]. Higher general and specific causes of mortality in all or specific age groups have been identified for people with serious medical and mental illnesses [18, 19, 20, 21]. People with chronic and severe mental illness have lower life expectancies of between 13 and more than 30 years than the general population [50], and a loss of 8.8 life years (14.1 years for men and 5.7 years for women) was estimated by a study which compared people treated for SMI and the general population in Massachusetts, USA [2]. Also, using a nationwide hospital discharge registry, a study reported a wide difference in life expectancy at age 30 for the main mental disorder categories compared to the general population, particularly for functional psychosis other than schizophrenia/affective psychosis (15.9 years lost), substance abuse (15.6 years lost), and organic psychosis (14.8 years lost) for men and organic psychosis (22.6 years lost), mental retardation (14.7 years lost), and substance abuse (18.8 years lost) for women [46]. Emphasis has been made on management of suicide risk and physical illness, minimum polypharmacy, and improvement of accessibility to physical healthcare [51].

Social security and different forms of life insurance policies have greatly helped in stabilizing life expectancy; in spite of this, a growing number of beneficiaries with multiple chronic conditions still have reduced life expectancy. The burden and stress of chronic disease could erase decades of progress. Life expectancy in the USA is rising more slowly than in other parts of the developed world. Many blame the obesity epidemic and related health conditions for the worsening health of the American population.

Functional limitations, including difficulty walking across the room or preparing meals, and health problems, such as high blood pressure, cancer, and diabetes, also predicted greater odds of experiencing a fall for adults 65 and older. Previous research indicates that older African Americans were more likely to live in extended family households. The availability of assistance at home could help older adults avoid scenarios or behaviors that could lead to falls.

Medication side effect is another important factor influencing longevity [51, 52, 53, 54, 55, 56, 57]. People with chronic illness tend to stay compliant longer on medications with less side effect profiles. For example, many people living with HIV find it difficult to continue the treatment regimen due to the side effects [53, 58]. Hence, decreasing the toxicity and side effects of HIV drugs will increase longevity, as this will increase their life span by increasing the amount of time that patients can stay on the life-saving treatment regimen and also increase quality of life [52, 53, 54]. Similarly, the antituberculosis and anticancer drugs are known to have serious side effects that can impair drug compliance, thereby reducing the life span of the affected individual [55, 56, 57, 59, 60, 61, 62]. Bringing new drugs to market is an essential part of increasing the life expectancy of young people with HIV, but lowering the drugs’ toxicity may have even greater health benefits for all HIV patients [52, 54]. Some side effects, such as increased cardiovascular risk, also cause problems that directly contribute to premature mortality and reduced life.

In spite of the current drug toxicity levels, young people with HIV add nearly 2 years to their lives by initiating HIV treatment regimens soon after infection [52]. If a new drug has a low toxicity and is well-tolerated by the patients, then they are more likely to take it regularly so that it is as effective as possible, and this will add to their life span. Reduction in the toxicity of new drugs has been associated with increase in the patient’s quality-adjusted life expectancy by as much as 11%, or more than 3 years [52]. “Quality-adjusted life years” and “quality-adjusted life expectancy” are measures that are used to determine the value of different medical actions. For example, a potentially life-saving drug that is highly toxic, causes so much discomfort, and leaves a patient debilitated would have a lower value than a life-saving drug that does not have such side effects. Furthermore, there exists the negative psychological impact of being on medications for a long time (and in some cases a lifetime), which is in turn detrimental on quality of life and longevity.

Infectious diseases are a significant health concern especially in developing countries, and this has significantly contributed to life expectancy [24, 25, 26, 27, 28, 29]. Of particular importance is the interface between the immune system and invading bacteria or virus and the proteins that protrude through the outer cell membrane of the bacteria or virus. Because these outer membrane proteins are on the outside of the antigenic cells, they are visible to the human immune system and therefore are targeted by antibodies. Antibodies are so tuned to recognize the three-dimensional structure of outer membrane proteins that they can attach to them with lock-and-key specificity, thereby labeling the foreign bacteria cell for elimination.

Mutations in the genes that code for outer membrane proteins can produce changes in the protein’s structure, and if the key then no longer fits the lock, the genetic mutations allow the bacterium or virus to evade recognition by antibodies [9, 25, 29]. The intense selective pressure on the disease-causing microorganism to survive the immune response, coupled with increased mutation rates, produces the incredibly fast rate of genomic change in infectious organisms. Mutations occur randomly throughout the genome, but because they help the microorganism avoid elimination by the immune system, changes in outer membrane proteins appear much more often than would be expected by chance in the surviving organism. Furthermore, this initial burst of mutations during the acute phase of infection allows the bacteria or virus to survive the host’s immune response, and this helps to establish a chronic infection including HIV and tuberculosis. In addition, the already weakened or compromised immunity sets a vulnerable pace for repeated reinfections or other new infections [24, 25, 26, 27, 28, 29]. These infections eventually become chronic and invariably affect longevity.

The chronicity of these medical illnesses, persistent and recurrent symptoms, impairment in functioning capacity, other adverse and enduring environmental psychosocial burdens, and even the thought of these can also in turn affect quality of life and subsequently lower life expectancy. Although HIV- and tuberculosis-infected and cancer-affected patients under antiretroviral (arbacire, nevirapine), antituberculosis drug (isoniazid and cycloserine), and anticancer medication (methotrexate) therapy infrequently suffer acute organic psychotic complications, the chronicity of the disease places them at greater risk for psychiatric comorbidity than the general population [63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77].

The terms “quality of life” refers to the physical, psychological, and social domains of health, viewed as distinct areas that are influenced by a person’s experiences, beliefs, expectations, and perception [78], (“which is referred to here collectively as perceptions of health”). Two things are significant in the above definition: the first is the subjective nature of QOL, and second is the need for a Clinician to assess all those areas of life considered as having significant impact on QOL. Quality of life assessment measures changes in physical, functional, mental, and social health in order to evaluate the human and financial cost and benefits of new programs and interventions [78, 79].

Quality of life therefore is impaired in many ways by the individual’s level of independence, social relationships, personal beliefs, and their relationship to salient features of the environment in addition to their physical health and psychological state. Quality of life also consists of fulfilling needs, meeting of social expectations, and assessing opportunities by using abilities. Abilities are impaired by ill health and worse still chronic medical illnesses [78, 79]. The services rendered by healthcare givers in mental health help to moderate social demands, supplement opportunities, and restore abilities. Quality of life can be altered by both the immediate and the long-term consequences of treatment especially the case of chronic illnesses [80]. Since 1948, when the WHO defined health as being not only the absence of disease and infirmity but also the presence of physical, mental, and social well-being, quality-of-life issues and well-being have taken the center stage in healthcare practices and research [78, 79, 81]. Several studies have shown that chronic medical and mental illnesses often impair or have negative impacts on the quality of life and subjective well-being of persons across a whole range of areas [80, 82, 83, 84, 85, 86, 87, 88, 89].

There has been a growing interest during the past decades for assessing determinant factors of patients’ health-related quality of life (HRQOL), especially in chronic diseases [78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89]. Diabetes mellitus, HIV, tuberculosis, hypertensive, cancer, schizophrenia, and dementia are some of these chronic diseases that involve people of all races and to some extent all ages. They are considered common chronic diseases in most countries, and their prevalence has continued to increase. Several studies have shown that chronic illnesses often impair or have negative impacts on the quality of life and subjective well-being of persons across a whole range of areas [80, 82, 83, 84, 85, 86, 87, 88, 89].

Tuberculosis, HIV, and cancer diseases weaken patients’ physical functioning and impair their quality of life and hence may affect life expectancy [82, 83, 84, 85]. It has become important that TB and HIV control programs as well as cancer awareness and prevention programs at public health clinics design strategies to improve the quality of health and life of these patients. In patients with chronic diseases, all predicted domains of quality of life (QOL), including general health perceptions, somatic sensation, psychological health, spiritual well-being, and physical, social, and role functioning, all tend to be negatively affected [86, 87, 88, 89, 90, 91, 92, 93]. Social stigmatization, isolation, pill burden, long duration of therapy, sexual dysfunction, loss of income, and fear were additional specific problems related to chronic medical conditions [80, 82, 83, 84, 85, 86, 87, 88]. Despite available curative therapy, TB and its treatment still have significant short- and long-term consequences on patients’ QOL [82, 83, 86, 87, 88, 89, 90, 91, 92, 93]. QOL has also been characterized as “the ultimate goal of all health interventions” [81].

Advertisement

2. Aim

The aim of this study, therefore, was to determine the impact of chronic medical and neuropsychiatric disorders (HIV, tuberculosis, diabetes mellitus, hypertension, schizophrenia, and dementia) on life expectancy and the role of quality of life and well-being.

Advertisement

3. Methodology

Following ethical approval and informed consent from the participants, 20 subjects from each group of HIV, tuberculosis, diabetes mellitus, hypertension, schizophrenia, and dementia were recruited based on the study’s inclusion and exclusion criteria. The study group comprised patients already diagnosed by the consultant physicians at their respective specialty clinics at the University of Port Harcourt Teaching Hospital and on treatment and have been regular on follow-up at their respective outpatient clinics. Participants were recruited through a simple random sampling. Those recruited were within 30–40 years of age, whose illness duration was within 3–5 years. Thirty-five normal individuals (five for each medical condition) were selected also via simple random sampling from among staff of the hospital, matched for age and sex, as controls.

Both subjects and controls were administered the study’s instruments including the sociodemographic/clinical questionnaire, WHO Composite International Diagnostic Interview (WHO CIDI), and the WHOQOL-Bref. The data were analyzed using the SPSS version 20 statistical package. The cohorts and control were followed up for clinic attendance, dropout, quality of life, death, and survival rates after 5 years. Confidence interval was set at 95%, while P-value of less than 0.05 was considered statistically significant (Tables 1 and 2).

Advertisement

4. Results

VariableDMHypertensionHIVTBCancerSchizoDementia
Age
30–39 years9 (45%)6 (30%)12 (60%)9 (45%)7 (35%)11 (55%)0 (0%)
40–49 years11 (55%)14 (70%)8 (40%)11 (55%)13 (65%)9 (45%)20 (100%)
Sex
Female12 (60%)10 (50%)10 (50%)9 (45%)10 (50%)12 (60%)11 (55%)
Male8 (40%)10 (50%)10 (50%)11 (55%)10 (50%)8 (40%)9 (54%)
Marital status
Married10 (50%)8 (40%)8 (40%)9 (45%)12 (60%)6 (30%)14 (70%)
Divorce2 (10%)1 (5%)2 (10%)3 (15%)2 (10%)0 (0%)0 (0%)
Separated3 (15%)3 (15%)3 (15%)3 (15%)1 (5%)5 (25%)3 (15%)
Single3 (15%)4 (20%)6 (30%)4 (20%)3 (15%)9 (45%)1 (5%)
Widowed2 (10%)4 (20%)1 (5%)1 (5%)1 (5%)0 (0%)2 (10%)
Education
Primary2 (10%)3 (15%)3 (15%)3 (15%)2 (10%)2 (10%)2 (10%)
Secondary8 (40%)7 (35%)4 (20%)7 (35%)6 (30%)10 (50%)5 (25%)
Tertiary9 (45%)8 (40%)7 (35%)7 (35%)11 (55%)7 (35%)13 (65%)
None1 (5%)2 (10%)1 (5%)3 (15%)0 (0%)1 (5%)0 (0%)
Occupation
Managers2 (10%)1 (5%)0 (0%)0 (0%)0 (0%)0 (0%)3 (15%)
Professionals3 (15%)1 (5%)1 (5%)0 (0%)4 (20%)0 (0%)4 (20%)
Clerical support workers5 (25%)5 (25%)4 (20%)5 (25%)4 (20%)0 (0%)2 (10%)
Service and sales workers2 (10%)4 (20%)4 (20%)5 (25%)3 (15%)3 (15%)3 (15%)
Skilled agricultural forestry and fishery workers4 (20%)5 (25%)2 (10%)4 (20%)2 (10%)4 (20%)2 (10%)
Craft and related trade workers2 (10%)1 (5%)4 (20%)3 (15%)3 (15%)4 (20%)2 (10%)
Plant and machine operators and assemblers1 (5%)1 (5%)3 (15%)1 (5%)2 (10%)3 (15%)1 (5%)
Elementary occupation1 (5%)1 (5%)2 (10%)2 (10%)2 (10%)6 (30%)1 (5%)
Armed forces occupation0 (0%)1 (5%)1 (5%)0 (0%)0 (0%)0 (0%)0 (0%)
Income
Low5 (25%)4 (20%)8 (40%)9 (45%)6 (30%)11 (55%)7 (35%)
Average13 (65%)14 (70%)11 (55%)10 (50%)18 (90%)9 (45%)6 (30%)
High2 (10%)2 (10%)1 (5%)1 (5%)1 (5%)0 (0%)7 (35%)

Table 1.

Sociodemographic variables of patients with diabetes, hypertension, HIV, tuberculosis, cancer schizophrenia, and dementia.

Medical/mental conditionRespondentsDomains of quality of life
Domain 1 (physical)Domain 2 (psychological)Domain 3 (social relationship)Domain 4 (environment)GHF
DMControl51.97 ± 14.7756.20 ± 22.1957.51 ± 26.1352.01 ± 16.9148.34 ± 22.44
Subjects44.98 ± 13.06456.60 ± 24.91448.06 ± 26.11444.95 ± 14.83147.98 ± 21.896
HypertensionSubjects45.98. ± 13.06446.60 ± 24.91453.06 ± 26.11456.95 ± 14.83150.98 ± 21.896
Control60.46 ± 12.78861.05 ± 13.36266.80 ± 21.37859.62 ± 16.50351.91 ± 23.319
HIVSubjects53.70 ± 10.10348.67 ± 15.01646.84 ± 21.03250.33 ± 10.45663.83 ± 20.349
Control66.36 ± 13.69867.85 ± 27.87057.09 ± 14.88867.50 ± 24.10266.61 ± 22.418
TBSubjects43.18 ± 12.04444.60 ± 32.82344.06 ± 37.14145.85 ± 11.23646.98 ± 23.493
Control61.26 ± 13.42862.05 ± 11.12265.71 ± 23.24156.71 ± 15.41252.78 ± 14.271
SchizoSubject41.22 ± 13.01553.40 ± 22.81346.16 ± 37.21345.39 ± 14.62243.15 ± 21.533
Control62.46 ± 12.64459.06 ± 53.36262.80 ± 27.37857.62 ± 16.50354.91 ± 23.100
HIVSubject49.23. ± 13.07259.63 ± 24.15252.06 ± 15.34558.95 ± 14.51153.15 ± 21.414
Control67.36 ± 17.61468.85 ± 38.83356.09 ± 17.75563.50 ± 34.10765.61 ± 29.411
CancerSubject41.98 ± 83.06242.60 ± 74.21547.06 ± 76.87745.95 ± 25.83743.98 ± 84.819
Control66.46 ± 12.78867.05 ± 13.36266.74 ± 28.41462.62 ± 19.41164.91 ± 23.744
DementiaSubject41.70 ± 75.11145.67 ± 31.07545.84 ± 91.92345.33 ± 17.41147.83 ± 29.384
Control58.69 ± 13.1757.28 ± 56.3958.49 ± 53.4454.33 ± 29.8360.62 ± 34.71
Statistical analysisP = 0.001P = 0.001P = 0.002P = 0.004P = 0.24

Table 2.

Quality of life using the WHOQOL-Bref of subjects and controls with diabetes mellitus, hypertension, HIV, tuberculosis, schizophrenia, cancer, and dementia.

DM, diabetes mellitus; HPT, hypertension; HIV, human immunodeficiency virus; TB, tuberculosis; GHF, general health facet.

Advertisement

5. Discussion

Young adults from 35 years and above predominated the study group. Similarly, younger age adults were more prevalent among the HIV, tuberculosis, and schizophrenia groups than the group with hypertension and cancer. The dementia group was composed of entirely younger age adults. Infectious diseases both sexually and nonsexually infections were predominantly represented by patients in early adulthood [4, 7]. Similarly, tuberculosis is an infective disease, and exposure to it may be more in adults who work in healthcare facilities and are mostly caregivers close to already infected persons [7, 8, 9]. Tuberculosis is also common in individuals whose immunity may have waned due to poor nutrition, alcohol use, stress, and other emotional illnesses, in most times occasioned by the medical illness, as well as other infective diseases [7, 8, 9]. HIV had the most of youngest population with age group 30–39 years forming 60%. This is in line with the earlier finding that HIV is more prevalent among young persons [24, 27]. Similarly, most cases of schizophrenia usually begin in early adulthood except paraphrenia that occurs among the elderly [21]. Hebephrenia, characteristically, one of the most early-onset and worst prognoses was excluded the same way as those with AIDS-defined illness that were excluded among the HIV group. Paranoid schizophrenia was the most common of the schizophrenic group.

Apart from the influence of genetic predisposition, diabetic mellitus and hypertension are largely a disease of lifestyle including unhealthy eating habits, alcohol intake, and sedentary lifestyle, which would be mostly displayed among adults [4, 13, 42, 48, 49, 50]. Hypertension is typically a disease of older adults but can occur in younger ages [12, 13, 14]. In this study, the majority of patients with hypertension were in the 40–49 age group. Cancers can occur in any age group [93, 94, 95, 96, 97], and those in this study ranged from lung, prostate, breast, cervical, blood, and bone cancers to cancers of the gastrointestinal tract. Dementia is generally a disease of advanced age but could present as presenile [98, 99, 100, 101, 102]. Even though all dementia participants sampled in this study were within the age group of 40–49, a majority were presenile. Patients with vascular dementia were excluded to reduce the influence of high blood pressure on this group. Overall, all the chronic illnesses in this study span from young to older ages. Therefore the choice of a fairly mid-age as inclusion criteria for respondents was to reduce the impact of extremes of age on the study variable particularly quality of life and life span. However, this may have contributed to the low mortality rate in this study.

In the study, female gender was slightly higher among all subjects with 56%. Females generally have better healthcare-seeking behavior and tend to have lower mortality rate at all ages [103]. So, even though hypertension has higher prevalence in community studies [6, 13, 17], most hospital-based studies show slightly higher prevalence in females. This is in addition to biological and cultural vulnerability of HIV infection [104]. Cancer was slightly higher among females, and this could also be due to the same reason that females report symptoms more readily than do males [103, 104].

The majority of the respondents were married. However, illnesses that have predominantly onset in early adulthood like schizophrenia or common among young adult like HIV had a high percentage of single people [21, 24, 27]. In addition to being predominant among young people, HIV and schizophrenia are associated with a high level of stigma [1, 77, 105], although stigma in the former seems to have reduced significantly over the years. Persons affected with schizophrenia particular early-onset type tend to have difficulty forming or sustaining relationship or even get married, and even those who are already married may face a high risk of separation due to fear of transmission.

A majority of the respondents were engaged in middle-class occupation followed by the lower cadre occupation. Hypertension and dementia which are conditions seen common in advance age were most common among the first-class occupations, while cancer, TB, HIV, and schizophrenia were more prevalent among those with lower cadre occupation. Similarly, about 95% of the respondents fall within low- and medium-income earners. A rewarding and satisfying job or occupation is key to good quality of life and by extension prolongs life span [78, 79, 80, 81, 82, 83, 84]. Because of the stigma associated with HIV, tuberculosis, schizophrenia, and to some extent cancer [1, 105, 106], there is reduced opportunity to secure sustained employment, so most of these individual settle for menial jobs and petty trading. Even those who had better jobs are sometimes laid off due to chronic illnesses especially in the private sector. Diabetes, hypertension and pre-senile dementia, though without risk from job discrimination, can be the cause of job dissatisfaction due to poor functioning and performance following disabling symptoms.

The cost of continuing treatment in chronic medical and mental disorders is usually huge on sufferers and their families [30]. This often is a major reason for poor drug compliance and in some cases treatment discontinuation [60, 61, 62] and may largely contribute to mortality [51, 58]. A majority of the respondents were low- and medium-income earners and may have difficulty in financing the management of their illness. This may reduce quality of life as well as life span. From the study, the dropout rates were high among dementia patients, followed by diabetes mellitus and schizophrenia. This may be due to financial difficulty or poor insight.

Quality of life among all respondents was below average on almost all domains and was statistically significant on all domains except the general health facet. The controls all had better quality of life as they all scored above average. Cancer and tuberculosis patients scored lowest on quality of life particularly both on physical and psychological domains and on social domains for the later. Apart from specific symptoms of these two medical conditions, they are usually associated with weight loss and extreme weakness, and as such the patient may have difficulty carrying out daily activities. In this case, physical domain of quality of life may be impaired. Psychological domains of quality of life of people suffering from chronic illnesses are usually first to be affected [64, 65, 66, 67, 68, 69, 70, 71, 72, 73]. Cancers are associated with some level of stigma but not as high as seen in tuberculosis. The high level of stigma and discrimination associated tuberculosis usually affects the social domain of quality of life [82, 83, 106, 107]. Diabetes mellitus was the next with poor quality of life especially on physical and environmental domains, giving credence to a number of studies [107, 108, 109, 110]. Diabetes presents with a lot of physical symptoms and risk of systemic damage and requires strict drug and dietary compliance. This may have contributed to the high rate of dropout and poor quality of life.

Hypertension had the best quality of life on all domains followed by HIV. These two conditions were equally found to have lower crude mortality rates. Generally, the study found that better quality of life directly correlated with higher person-years lived and inversely correlated with crude mortality rates (Table 3). Hypertension equally presents with a number of physical symptoms, the risk of systemic damage, and the need for strict drug compliance. However, it is not associated with any form of stigma, and a majority of respondents were average-income earners. The level of stigma and discrimination that was associated with HIV two decades ago has drastically reduced following massive public awareness. Also, governments of different countries and the WHO have continued to embark on different intervention strategies including free antiretroviral medications. These effects may have combined to reduce the financial and social burden including stigma and discrimination among HIV-positive individuals.

ConditionNo. of alive at beginning of studyAverage quality of lifeNo. of deathsDropoutMean person-years livedCrude mortality rate
Hypertension2049.84 ± 26.1242 (10%)1 (5%)2.310.844
Diabetes2045.31 ± 71.0123 (15%)2 (10%)2.151.395
Tuberculosis2041.92 ± 13.0214 (20%)0 (0%)1.213.306
Schizophrenia2053.43 ± 22.0811 (5%)2 (10%)3.420.292
HIV2047.51 ± 31.4112 (10%)1 (5%)2.830.707
Cancer2042.61 ± 78.0334 (20%)1 (5%)1.852.162
Dementia2048.19 ± 85.1512 (10%)3 (15%)3.210.623
Control3567.22 ± 52.810 (0%)1 (5%)

Table 3.

Record of death and survival of respondents.

Quality of life in people living with HIV (PLWHIV), dementia, schizophrenia, and tuberculosis was significantly affected, more on the psychological and social domains compared with diabetes mellitus, hypertension, and cancer diseases [92, 107, 108, 109, 110, 111, 112]. This suggests that the stigma and social rejection associated with the communicable disease may play a significant role in the development of psychological illness. This also implies that even though psychological burden is equally common in the diabetes mellitus and hypertension and affecting quality of life generally, the presence of psychological burden and trauma that may be associated with PLWHIV and tuberculosis tended to have more severe negative impact on quality of life [65, 66]. Again, there is a possibility that there may have been existing psychological illnesses either undiagnosed or untreated that may have made them engage in risky sexual behaviors that may have made them vulnerable to infectious diseases.

The presence of symptoms of tuberculosis, cancers, hypertension, and diabetes mellitus alone appears to be more disabling than those in PLWHIV, dementia, and schizophrenia bearing in mind that acute cases were excluded. Moderate to severe cases of diabetes mellitus, hypertension, and tuberculosis cause more symptoms, and they are more disabling. This may account for the better quality of life among PLWHIV on the physical domain and the lower quality of life scores on both the physical and environment domains, among them, than the PLWHIV in this study. HIV not complicated with AIDS is most of the time symptom free or stable on medication, and this stability is often less sensitive to adverse environmental factors unlike in diabetes mellitus, hypertension, and tuberculosis where little adverse changes in the environment could affect profoundly the patients who had hitherto remained stable on medications [12, 22, 30, 39, 43, 52]. Such changes may include change in income level, employment, marital status (prolonged difficulty, disharmony, separation, divorce, or widowhood), and poor drug adherence with immediate exacerbation of symptoms.

A majority of the patients in all medical conditions fared well on most domains. The possible reasons are their focus on physical strength (e.g., evident physical health, absence of symptoms, ability to work around, available family support, and a strong religious belief) than on their weaknesses (e.g., social discrimination). On Domains 1 and 4, PLWHIV had better performance on quality of life, followed by hypertension and diabetes mellitus, while tuberculosis had the least in similar domains. Furthermore, PLWHIV also scored higher on GHF than the other medical conditions.

Chronic medical and mental diseases account for multiple burdens for patients, including the necessity to deal with pain, suffering, reduced quality of life, premature mortality, financial costs, and familial emotional trauma [12, 30, 32, 72, 73]. The risk factors for mental health problems among patients suffering from chronic medical illnesses are complex [72, 73, 113]. Usually, the more serious the somatic disease and symptoms are, the more probable it will be to be accompanied by mood and/or anxiety symptoms of variable severity [72, 73]; conditions arising after the somatic disease are diagnosed. In other words, even if those with dual diagnoses were excluded from the study, it clearly understood that most chronic medical conditions tend to be associated with some emotional disturbance. Failure to manage such mental health problems increases the patients’ probability of suffering from complications, even lethal.

In chronic medical conditions, functionality may be severely impaired due to chronic psychogenic and somatic pain, frequent hospital admissions, and dependency from medical and nursing personnel. These are all markers of poor quality of life and well-being. It is important to mention that most of the mortalities in chronic medical conditions may not be due to the direct complication of the disease, rather a cumulative outcome of social and psychological dissatisfaction of the condition. Sufferers maintain the feeling that they have come to the end of the road and seek the easiest escape rooting out of the problem which is suicide [114, 115, 116, 117]. In addition, research has pointed out a relationship between sustained emotional disturbance especially depression and reduced immunity. This may be worse among chronically ill patients, and this makes them more vulnerable to recurrent infections or reinfections. Good quality of life and well-being are a measure of satisfaction in major areas of life including mood stability and affording basic nutrition which will sustain immunity.

Most chronic illnesses particularly HIV, cancer, and tuberculosis in sub-Saharan Africa are classic examples of diseases with both medical and social dimensions, characterized by its close relation to poor socioeconomic conditions [27, 28, 29, 30, 31]. For instance, in tuberculosis, a higher risk of acquiring active disease occurs with alcoholism, smoking [48, 49], intravenous drug abuse [48, 49, 58, 74], diabetes mellitus, HIV infection, overcrowding, and other factors. The abovementioned risk factors are very prevalent among populations with reduced quality of life and well-being and increase risk of having HIV and progression from latent TB to active TB [77].

From the study, mortality was the highest among tuberculosis and cancer patients, followed by patients with diabetes mellitus. Schizophrenia had the lowest mortality after 5 years. There was no mortality among the control within the period. Correspondingly, mortally was the highest among the groups with the lowest quality of life. Quality of life is an indicator of total well-being and optimal health; therefore, if it is low, then it is an indication that the individual may not be enjoying good health. The finding among the diabetes group is in line with the earlier report that reduced life expectancy at age 15 by 1.3 years for men and 2.0 years for women in Canada [47] and a BMI of 40–45 kg/m2 were associated with a 10-year reduction of life expectancy at age 35 compared to a BMI of 22.5–25 kg/m2 [118]. Causes of mortality may be due to organ damage, complication of medication, systemic damage, or hemodynamic changes. Actual or direct causes of the deaths could not be ascertained as many of the deaths did not occur in the hospital. Mortality from tuberculosis and cancer tends to be high with a low rate of survival. Mortality in severe chronic mental illness is recognized to be raised, and underlying causes may be multiple. However, the death rate was lowest among schizophrenics in this study. This may be due to the fact the schizophrenics were predominantly young population and also because those with poor prognosis like hebephrenia and disorganized were excluded from the study and only paranoid and catatonic types which carry better prognosis were included. This finding however differs from the earlier finding that any psychiatric diagnosis was associated with a 65% higher than expected total mortality in a case register study in a British primary care cohort [119].

Coronary heart disease accounts for threefold elevated mortality in young adults with severe mental illness [120] and diabetes, while stroke is usually a complication of long-standing hypertension. Long-term antipsychotic use and adverse lifestyle choices (e.g., obesity, smoking, poor diet, illicit drug use, and physical inactivity) are implicated in increased risk of cardiovascular events in these populations [1, 51, 120, 121, 122] and clearly need higher levels of consideration in order to improve health and survival, as well as the better-known risks of suicide and violent deaths. The causal pathways between mental disorder and premature mortality are multiple, making life years lost an important outcome measure in this population.

Life expectancy is a commonly used indicator for how longevity may be impaired by specific long-term exposures (e.g., smoking, obesity, ethnicity, and socioeconomic status) or chronic conditions of ill health or risk (e.g., diabetes mellitus) [48, 49] and provides an alternative measure to determine the influences of different exposures for the purpose of highlighting premature mortality at younger ages in potentially vulnerable groups. It is therefore primarily a measure of impact and should be seen as complementary to more elaborate studies using measures of effect. As a measure, life expectancy analyses offer an important means of communicating impact on survival to policy makers. Current smoking is associated with around 4 to 5 life years lost for both genders [48, 49].

Clearly the mechanisms through which medical and mental disorders are associated with premature mortality will include the effects of these individual risk factors (e.g., smoking behavior, risk of diabetes, etc.) as well as other factors (such as risk of suicide or accidents and direct effects of mental distress on cardiovascular risk). Excess mortality associated with mental disorders has been demonstrated to be predominantly due to “natural” causes [18, 119, 120] although mental health service provision is often focused on preventing more rare outcomes of suicide and violent death [115, 116, 117]. If improving overall survival is to be considered as an alternative priority, much more efforts are clearly required to address the challenges of improving general health in people with mental disorders through medical services, socioeconomic support, and physical health promotion strategies [51].

It is important to note that a good number of psychosocial and clinical factors, like increased age, marital status (married), later age of onset of illness, education, employment, average to high monthly income, shorter duration of illness, longer duration of treatment, and emotional stability, may affect the quality of life and other outcome of the medical conditions. The implication of this is that these factors have to be addressed in the holistic management of these and indeed other chronic medical conditions.

Advertisement

6. Conclusion

The findings of this study support the impression that chronic medical conditions are associated with reduced quality of life, which, together with a number of sociodemographic and clinical factors, in turn affect life expectancy. The results support the call that the management of patients with these medical conditions should necessarily include attention to the mental health status of the sufferers.

Advertisement

7. Recommendations

Based on the findings of this study that chronic medical conditions are commonly associated with reduced quality of life and well-being, which further affect longevity, it becomes imperative that renewed efforts by government, aimed at both primary and secondary prevention, be intensified for these chronic medical conditions.

References

  1. 1. Gray R, Hardy S, Anderson KH. Physical health and severe mental illness: If we don’t do something about it, who will? International Journal of Mental Health Nursing. 2009;18:299-300
  2. 2. Phillips RS, Wenger NS, Teno J, et al. Choices of seriously ill patients about cardiopulmonary resuscitation: Correlates and outcomes. The American Journal of Medicine. 1996;100:128-137
  3. 3. Hagerty RG, Butow PN, Ellis PM, et al. Communicating prognosis in cancer care: A systematic review of the literature. Annals of Oncology. 2005;16:1005-1053
  4. 4. Centres for Disease Control and Prevention. HIV/AIDS Surveillance Report. 2004;12(1):1-42
  5. 5. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Research and Clinical Practice. 2010;87(1):4-14
  6. 6. Unachukwu CN, Agomoh DI, Alasia DD. Pattern of non-communicable diseases among medical admissions in Port Harcourt, Nigeria. Nigerian Journal of Clinical Practice. 2008;11(1):14-17
  7. 7. Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle. 1991;72(1):1-6
  8. 8. World Health Organization. Global Tuberculosis Control. Geneva, Switzerland: World Health Organization; 2010. Available from: http://www.who.int/tb/publications/global_report/en/index.html
  9. 9. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. Journal of the American Medical Association. 1999;282(7):677-686
  10. 10. Gwatkin D, Guillot M, Heuveline P. The burden of disease among the global poor. Lancet. 2000;354:586-589
  11. 11. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world. Global burden of disease. Lancet. 1997;349:1269-1276
  12. 12. Kearney PM, Whelton M, Renoids K, Muntner P, Whenton KP. Global burden of hypertension: Analysis of worldwide data. Lancet. 2005;365:217-223
  13. 13. Erhun WO, Olayiwola G, Agbani EO, Omotoso NS. Prevalence of hypertension in a University Community in South Western Nigeria. African Journal of Biomedical Research. 2005;8:15-19
  14. 14. Van de Sande MAB, Bailey R, Faal H, Banya WA, Dolin P, Nyan OA, et al. Nationwide prevalence study of hypertension and related non-communicable diseases. Tropical Medicine & International Health. 1997;2:1039-1048
  15. 15. Briganti EM, Shaw JE, Chadban SJ, Zimmet PZ, Welborn TA, McNeil JJ, et al. Untreated hypertension among Australian adults: The 1999-2000 Australian diabetes, obesity and lifestyle study. The Medical Journal of Australia. 2003;179:135-139
  16. 16. Adefuye BO, Adefuye PO, Oladepo TO, Familoni OB, Olurunga TO. Prevalence of hypertension and other cardiovascular risk factors in an African urban, sub-urban religious community. Nigerian Medical Practitioner. 2009;55(1-2):4-8
  17. 17. Wokoma FS, Alasia DD. Blood pressure pattern in Barako: A rural community in Rivers State, Nigeria. Nigerian Health Journal. 2011;11:813
  18. 18. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. The British Journal of Psychiatry. 2000;177:212-217
  19. 19. Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, et al. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom’s General Practice Research Database. Archives of General Psychiatry. 2007;64:242-249
  20. 20. Osborn D, Levy G, Nazareth I, King M. Suicide and severe mental illnesses. Cohort study within the UK general practice research database. Schizophrenia Research. 2008;99:134-138
  21. 21. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: A concise overview of incidence, prevalence, and mortality. Epidemiologic Reviews. 2008;30:67-76
  22. 22. Pickering TG, Devereux RB, James GD, et al. Environmental influences on blood pressure and the role of job strain. Journal of Hypertension. Supplement. 1999;341:120-124
  23. 23. Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Annals of Internal Medicine. 2003;139(9):761-776
  24. 24. Windle M. The trading of sex for money or drugs, sexually transmitted diseases (STDs) and HIV related risk behaviors among polysubstance use and alcoholic inpatients. Drug and Alcohol Dependence. 1997;49:33-38
  25. 25. Johnson RT. In: Johnson A, editor. HIV in Viral Infections of the Nervous System. 2nd ed. PA, USA: Lippincott-Raven; 1998. pp. 287-331
  26. 26. Center for Disease Control and Prevention. Prevention and treatment of tuberculosis patients infected with human immunodeficiency virus: Principles of therapy and revised recommendations. Morbidity and Mortality Weekly Report. 1998;47(RR-20):1-51
  27. 27. Bharat S, Aggleton P. Facing the challenge: Household responses to AIDS in Mumbai, India. AIDS Care. 1999;11:31-44
  28. 28. Bird ST, Bogart LM, Delahanty DL. Health-related correlates of perceived discrimination in HIV care. AIDS Patient Care STDS. January 2004;18(1):19-26
  29. 29. Courtwright A, Turner AN. Tuberculosis and stigmatization: Pathways and interventions. Public Health Reports. 2010;125(Supplement 4):34-42
  30. 30. Esteghamati A, Khalilzadeh O, Anvari M, Meysamie A, Abbasi M, Forouzanfar M, et al. The economic costs of diabetes: A population-based study in Tehran Iran. Diabetologia. 2009;52(8):1520-1527
  31. 31. Rogacheva MG. Social aspects in tuberculosis among mental patients. ProblemyTuberkuleza. 2002;10:13-16
  32. 32. World Health Organization. Burden: Mortality, morbidity and risk factors. Global Status Report on Non-communicable Diseases. 2010. Available from: http://www.who.int/nmh/publications/ncd_report_chapter_1.pdf [Accessed: 01 October 2012]
  33. 33. Issa BA, Yussuf AD, Kuranga SI. Depression comorbidity among patients with tuberculosis in a university teaching hospital outpatient clinic in Nigeria. Mental Health in Family Medicine. 2009;6:133-138
  34. 34. Deribew A, Tesfaye M, Hailmichael Y, et al. Common mental disorders in TB/HIV co-infected patients in Ethiopia. BMC Infectious Diseases. 2010;10:201. DOI: 10.1186/1471-2334-10-201
  35. 35. Chaudhry R, Mishra P, Mishra J, Parminder S, Mishra BP. Psychiatric morbidity among diabetic patients: A hospital-based study. Industrial Psychiatry Journal. 2011;19(1):47-49
  36. 36. De Ornelas Maia AC, Braga Ade A, Brouwers A, Nardi AE, De Oliveira e Silva AC. Prevalence of psychiatric disorders in patients with diabetes types 1 and 2. Comprehensive Psychiatry. 2012;53(8):1169-1173
  37. 37. Johnson J, Williams J, Rabkin J, et al. Axis 1 psychiatric symptomatology associated with HIV infection and personality disorder. The American Journal of Psychiatry. 1995;152:551-554
  38. 38. Myers H, Durvasula B. Psychiatric disorders in African, American men and women living with HIV/AIDS. Cultural Diversity and Ethnic Minority Psychology. 1999;5:249-262
  39. 39. Grange JM, Festenstein F. The human dimension of tuberculosis control. Tubercle and Lung Disease. 1993;74(4):219-222
  40. 40. Lerman I, Lozano L, Villa AR, et al. Psychosocial factors associated with poor diabetes self-care management in a specialized center in Mexico City. Biomedicine & Pharmacotherapy. 2004;58:566-570
  41. 41. Lin EH, Katon W, Von Korff M, et al. Relationship of depression and diabetes self-care, medication adherence, and preventive care. Diabetes Care. 2004;27:2154-2160
  42. 42. Peltzer K, Louw J, Mchunu G, Naidoo P, Matseke G, Tutshana B. Hazardous and harmful alcohol use and associated factors in tuberculosis public primary care patients in South Africa. International Journal of Environmental Research and Public Health. 2012;9(9):3245-3257
  43. 43. Rajeswari R, Balasubramanian R, Muniyandi M, Geetharamani S, Thresa X, Venkatesan P. Socio-economic impact of tuberculosis on patients and family in India. The International Journal of Tuberculosis and Lung Disease. 1999;3(10):869-877
  44. 44. Danaei G, Rimm EB, Oza S, Kulkarni SC, Murray CJ, et al. The promise of prevention: The effects of four preventable risk factors on national life expectancy and life expectancy disparities by race and county in the United States. PLoS Medicine. 2010;7:e1000248
  45. 45. Clarke CA, Miller T, Chang ET, Yin D, Cockburn M, et al. Racial and social class gradients in life expectancy in contemporary California. Social Science & Medicine. 2010;70:1373-1380
  46. 46. Hannerz H, Borga P, Borritz M. Life expectancies for individuals with psychiatric diagnoses. Public Health. 2001;115:328-337
  47. 47. Sikdar KC, Wang PP, MacDonald D, Gadag VG. Diabetes and its impact on health-related quality of life: A life table analysis. Quality of Life Research. 2010;19:781-787
  48. 48. Ozasa K, Katanoda K, Tamakoshi A, Sato H, Tajima K, et al. Reduced life expectancy due to smoking in large-scale cohort studies in Japan. Journal of Epidemiology. 2008;18:111-118
  49. 49. Tamakoshi A, Kawado M, Ozasa K, Tamakoshi K, Lin Y, et al. Impact of smoking and other lifestyle factors on life expectancy among Japanese: Findings from the Japan collaborative cohort (JACC) study. Journal of Epidemiology. 2010;20:370-376
  50. 50. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Preventing Chronic Disease. 2006;3:A42
  51. 51. Auquier P, Lancon C, Rouillon F, Lader M, Holmes C. Mortality in schizophrenia. Pharmacoepidemiology and Drug Safety. 2006;15:873-879
  52. 52. Rabkin JG, Ferrando S, Lin SH, Sewell M, McElhiney M. Psychological effects of HAART: A 2-year study. Psychosomatic Medicine. 2000;62:413-422
  53. 53. Ellen SR, Judd FK, Mijch AM, Cockram A. Secondary mania in patients with HIV infection. Australian and New Zealand Journal of Psychiatry. 1999;33:353-360
  54. 54. Barllett J. Addressing the challenges of adherence. Journal of Acquired Immune Deficiency Syndromes. 2002;29(Suppl 1):S-SO
  55. 55. Prasad R, Garg R, Verma SK. Isoniazid- and ethambutol-induced psychosis. Annals of Thoracic Medicine. 2008;3(4):149-151
  56. 56. Martin SJ, Bowden FJ. Ethambutol toxicity manifesting as acute onset psychosis. International Journal of STD and AIDS. 2007;18(4):287-288
  57. 57. Kennedy NA, Oluwaseun A, Denis AA, Chukwuemeka SP. Cycloserine induced-psychosis in a 22-year old male pharmacy student: A case report. American Journal of Psychiatry and Neuroscience. 2016;1:124-126
  58. 58. Chang CK, Hayes RD, Perera G, Broadbent M, Fernandes AC, et al. All-cause mortality among people with serious mental illness (SMI), substance use disorders, and depressive disorders in southeast London: A cohort study. BMC Psychiatry. 2010;10:77
  59. 59. Prasad CE, Krishnamurthy K, Murthy KJR. Psychiatric disorders in patients receiving anti-tuberculosis drugs. Indian Journal of Psychiatry. 1985;27(4):311-314
  60. 60. Bagchi S, Ambe G, Sathiakumar N. Determinants of poor adherence to anti-tuberculosis treatment in Mumbai, India. International Journal of Preventive Medicine. 2010;1(4):223-232
  61. 61. Manoharam E, John KR, Joseph A, Jacob KS. Psychiatric morbidity, patients’ perspectives of illness and factors associated with poor medication compliance among the tuberculous in Vellore, south India. The Indian Journal of Tuberculosis. 2001;48:77-80
  62. 62. Erhabor GE, Aghanwa HS, Yusuph M, Adebayo RA, Arogundade FA, Omidiora A. Factors influencing compliance in patients with tuberculosis on directly observed therapy at Ile-Ife, Nigeria. East African Medical Journal. 2000;77(5):235-239
  63. 63. Sulehri MA, Dogar IA, Sohail H, et al. Prevalence of depression among tuberculosis patients. Annals of Punjab Medical College. 2010;4:133-137
  64. 64. Jonas BS, Franks P, Ingram DD. Are symptoms of anxiety and depression risk factors for hypertension? Longitudinal evidence from the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Archives of Family Medicine. 1997;6:43-49
  65. 65. Katze S, Nevid JS. Risk factors associated with posttraumatic stress disorder symptomatology in HIV-infected women. AIDS Patient Care and STDs. 2005;19(2):110-120
  66. 66. Olley BO, Zeier MD, Seedat S, Stein DJ. Posttraumatic stress disorder among recently diagnosed patients with HIV/AIDS in South Africa. AIDS Care. 2005;17(5):550-557
  67. 67. Peltzer K, Naidoo P, Matseke G, Louw J, McHunu G, Tutshana B. Prevalence of post-traumatic stress symptoms and associated factors in tuberculosis (TB), TB retreatment and/or TB-HIV co-infected primary public health-care patients in three districts in South Africa. Psychology Health and Medicine. 2013;18(4):387-397
  68. 68. Engum A. The role of depression and anxiety in onset of diabetes in a large population-based study. Journal of Psychosomatic Research. 2007;62(1):31-38
  69. 69. Jaggarajamma K, Ramachandran R, Charles N, Chandrasekaran V, Muniyandi M, Ganapathy S. Psycho-social dysfunction: perceived and enacted stigma among tuberculosis patients registered under revised national tuberculosis control programme. The Indian Journal of Tuberculosis. 2008;55(4):179-187
  70. 70. Guruprasad KG, Niranjan MR, Ashwin S. A study of association of depressive symptoms among the type 2 diabetic outpatients presenting to a tertiary care hospital. Indian Journal of Psychological Medicine. 2012;34:30-33
  71. 71. Poongothai S, Anjana RM, Pradeepa R, Ganesan A, Umapathy N, Mohan V. Prevalence of depression in relation to glucose intolerance in urban south Indians: The Chennai Urban Rural Epidemiology Study (CURES-76). Diabetes Technology & Therapeutics. 2010;12:989-994
  72. 72. Katon WJ. Epidemiology and treatment of depression in patients with chronic medical illness. Dialogues in Clinical Neuroscience. 2011;13:7-23
  73. 73. Katon W, Lin EH, Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. General Hospital Psychiatry. 2007;29:147-155
  74. 74. Crosby G, Stall R, Paul J, Barrett D. Substances use and HIV risk profile of gay/bisexual males who drop substance abuse treatment. AIDS Education and Prevention. 2000;12:38-48
  75. 75. Black SA. Increased health burden associated with comorbid depression in older diabetic Mexican Americans. Results from the Hispanic Established Population for the Epidemiologic Study of the Elderly survey. Diabetes Care. 1999;22:56-64
  76. 76. Kaholokula JK, Haynes SN, Grandinetti A, Chang HK. Biological, psychosocial, and sociodemographic variables associated with depressive symptoms in persons with type 2 diabetes. Journal of Behavioral Medicine. 2003;26:435-458
  77. 77. Ogunrin AO, Odiase FE, Ogunniyi A. Reaction time in patients with HIV/AIDS and correlation with CD4 count: A case-control study. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2007;101(5):517-522
  78. 78. Levine S, Croog S. What constitutes quality of life? A conceptualization of the dimensions of life quality in healthy population and patients with cardiovascular disease. In: Wenger N, Mattson ME, Furgerg CD, Elinson J, editors. Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. New York: Le Jacq; 1998. pp. 46-58
  79. 79. Robinson S, Young T, Roos L. Estimating the burden of disease. Comparing administrative data and self-reports. Medical Care. l997;35(9):932-947
  80. 80. Testa MA, Hollenberg Anderson RA, Williams GH. Assessment of quality of life by patient and spouse during antihypertensive therapy with atenolol and nifedipine gastrointestinal therapeutic system. American Journal of Hypertension. 1991;4:363-373
  81. 81. Concepts of health-related quality of life. In: Patrick DL, Erickson P, editor. Health Status and Health Policy: Quality of Life in Health Care Evaluation and Resource Allocation. New York: Oxford University Press; 1993. pp. 76-112
  82. 82. Louw J, Peltzer K, Naidoo P, Matseke G, McHunu G, Tutshana B. Quality of life among tuberculosis (TB), TB retreatment and/or TB-HIV co-infected primary public health care patients in three districts in South Africa. Health and Quality of Life Outcomes. 2012;10:77. DOI: 10.1186/1477-7525-10-77
  83. 83. Weis SE, Pasipanodya JG. Measuring health-related quality of life in tuberculosis: A systemic review—Response. Health and Quality of Life Outcomes. 2010;8:7. DOI: 10.1186/1477-7525-8-7
  84. 84. Jia H, Uphold CR, Wu S, Reid K, Findley K, et al. Health-related quality of life among men with HIV infection: Effects of social support, coping and depression. AIDS Patient Care and STDs. 2004;18:594-603
  85. 85. Ghanbari A, Yekta ZP, Roushan ZA, Lakeh NM. Assessment of factors affecting quality of life in diabetic patients in Iran. Public Health Nursing. 2005;22(4):311-322
  86. 86. Haririan H, Moghadasian S, Aghajanlou A. Quality of life and its dimensions in diabetic patients referred to diabetes center of Tabriz medical university. Iranian Journal of Diabetes and Lipid Disorders. 2009;9(2):152-160
  87. 87. Brown J, Capocci S, Smith C, Morris S, Abubakar I, Lipman M. Health status and quality of life in tuberculosis. International Journal of Infectious Diseases. 2015;32:68-75
  88. 88. Aggarwal AN, Gupta D, Janmeja AK, Jindal SK. Assessment of health-related quality of life in patients with pulmonary tuberculosis under programme conditions. The International Journal of Tuberculosis and Lung Disease. 2013;17(7):947-953. DOI: 10.5588/ijtld.12.0299
  89. 89. Rajeswari R, Muniyandi M, Balasubramanian R, Narayanan PR. Perceptions of tuberculosis patients about their physical, mental and social well-being: A field report from south India. Social Science & Medicine. 2005;60(8):1845-1853. DOI: 10.1016/j.socscimed.2004.08.024
  90. 90. Adeyeye OO, Ogunleye OO, Coker A, Kuyinu Y, Bamisile RT, Ekrikpo U, et al. Factors influencing quality of life and predictors of low quality of life scores in patients on treatment for pulmonary tuberculosis: A cross sectional study. Journal of Public Health in Africa. 2014;5(2):88-92. DOI: 10.4081/jphia.366. Available from: https://www.publichealthinafrica.org/index.php/jphia/article/view/366/156
  91. 91. Balgude A, Sontakke S. Study of impact of antitubercular therapy on quality of life. Indian Journal of Medical Sciences. 2012;66(3-4):71-77
  92. 92. Wexler DJ, Grant RW, Wittenberg E, et al. Correlates of health-related quality of life in type 2 diabetes. Diabetologia. 2006;49:1489-1497
  93. 93. Brustugun OT, Moller B, Helland A. Years of life lost as a measure of cancer burden on a national level. British Journal of Cancer. 2014;111:1014-1020. DOI: 10.1038
  94. 94. Rachet B, Woods LM, Mitry E, Riga M, Cooper N, Quinn MJ, et al. Cancer survival in England and Wales at the end of the 20th century. British Journal of Cancer. 2008;99(Suppl 1):S2-S10
  95. 95. Rutherford MJ, Andersson TML, Møller H, Lambert PC. Understanding the impact of socioeconomic differences in breast cancer survival in England and Wales: Avoidable deaths and potential gain in expectation of life. Cancer Epidemiology. 2015;39:118-125
  96. 96. Rutherford MJ, Hinchliffe SR, Abel GA, Lyratzopoulos G, Lambert PC, Greenberg DC. How much of the deprivation gap in cancer survival can be explained by variation in stage at diagnosis: An example from breast cancer in the East of England. International Journal of Cancer. 2013;133(9):2192-2200
  97. 97. Siemerink EJM, Hospers GAP, Mulder NH, Siesling S, van der Aa MA. Disparities in survival of stomach cancer among different socioeconomic groups in north-east Netherlands. Cancer Epidemiology. 2011;35:413-416
  98. 98. Singh GK, Williams SD, Siahpush M, Mulhollen A. Socioeconomic, rural-urban, and racial inequalities in us cancer mortality: Part I—All cancers and lung cancer and part II—Colorectal, prostate, breast, and cervical cancers. Journal of Cancer Epidemiology. 2011;2011:107497
  99. 99. Dewey EM, Saz P. Dementia cognitive impairment and mortality in persons aged 65 and over living in a community a systematic review of literature. International Journal of Geriatric Psychiatry. 2001;16:751-761
  100. 100. Agüero-Torres H, Fratiglioni L, Guo Z, Viitanen M, Winblad B. Mortality from dementia in advanced age: A 5-year follow-up study of incident dementia cases. Journal of Clinical Epidemiology. 1999;52:737-743
  101. 101. Kammoun S, Gold G, Bouras C, Giannakopoulos P, McGee W, Herrmann F, et al. Immediate causes of death of demented and non-demented elderly. Acta Neurologica Scandinavica. Supplementum. 2000;176:96-99
  102. 102. Mitchell SL, Kiely DK, Hamel MB, Park PS, Morris JN, Fries BE. Estimating prognosis for nursing home residents with advanced dementia. JAMA. 2004;291:2734-2740
  103. 103. Nor K, Tlou S, Norr J. The threat of AIDS for women in developing countries. In: Cohen F, Durham JD, editors. Women Children and HIV. New York: Springer Publishing Co; 1993. p. 263
  104. 104. Gibson N, Cave A, Doering D, Ortiz L, Harms P. Socio-cultural factors influencing prevention and treatment of tuberculosis in immigrant and Aboriginal communities in Canada. Social Science and Medicine. 2005;61(5):931-942
  105. 105. De Bruyn T. HIV/AIDS and 1. Discrimination, 2. Stigma and Discrimination: Definitions and Concepts. Ottawa: Canadian HIV/AIDS Legal Network and the Canadian AIDS Society; 1999
  106. 106. Van Rie A, Sengupta S, Pungrassami P, Balthip Q, Choonuan S, Kasetjaroen Y, et al. Measuring stigma associated with tuberculosis and HIV/AIDS in southern Thailand: Exploratory and confirmatory factor analyses of two new scales. Tropical Medicine and International Health. 2008;13(1):21-30. DOI: 10.1111/j.1365-3156.2007.01971.x
  107. 107. Oliva J, Fernández-Bolaños A, Hidalgo A. Health-related quality of life in diabetic people with different vascular risk. BMC Public Health. 2012;12:812
  108. 108. Ahari SS, Arshi S, Iranparvar M, Amani F, Siahpush H. The effects of type II diabetes on quality of life. Journal of Ardabil University of Medical Sciences. 2008;8(4):394-402
  109. 109. Ahmadi A, Hasanzadeh J, Mediseh MR, Lashkari L. Factors affecting quality of life in patients with type 2 diabetes in Chaharmahal & Bakhtiari province. Journal of North Khorasan University of Medical Sciences. 2011;3(1):7-13
  110. 110. Borzou R, Salavati M, Safari M, Hadadinejad SH, Zandieh M, Torkman B. Quality of life in type II diabetic patients referred to Sina Hospital, Hamadan. Zahedan Journal of Research in Medical Sciences. 2010;13(4):43-46
  111. 111. Goldney RD, Phillips PJ, Fisher LJ, Wilson DH. Diabetes, depression, and quality of life—A population study. Diabetes Care. 2004;27:1066-1070
  112. 112. Larsson D, Lager I, Nilsson PM. Socio-economic characteristics and quality of life in diabetes mellitus/relation to metabolic control. Scandinavian Journal of Public Health. 1999;27:101-105
  113. 113. WHO. The World Health Report—Mental Health: New Understanding, New Hope. Geneva, Switzerland: WHO; 2001. Available from: http://www.who.int/whr/2001/en/
  114. 114. Demi A, Bakeman R, Richard S, Linda M, Brenda S. Suicidal thoughts of women with HIV infection: Effect of stressors and moderating effects of family cohesion. Journal of Family Psychology. 1998;12:344-353
  115. 115. Caldwell CB, Gottesman II. Schizophrenics kill themselves too: A review of risk factors for suicide. Schizophrenia Bulletin. 1990;16:571-589
  116. 116. Dutta R, Boydell J, Kennedy N, Van Os J, Fearon P, et al. Suicide and other causes of mortality in bipolar disorder: A longitudinal study. Psychological Medicine. 2007;37:839-847
  117. 117. McGirr A, Turecki G. What is specific to suicide in schizophrenia disorder? Demographic, clinical and behavioural dimensions. Schizophrenia Research. 2008;98:217-224
  118. 118. Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, et al. Body-mass index and cause-specific mortality in 900 000 adults: Collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083-1096
  119. 119. Baxter DN. The mortality experience of individuals on the Salford Psychiatric Case Register. I. All-cause mortality. The British Journal of Psychiatry. 1996;168:772-779
  120. 120. Fagiolini A, Goracci A. The effects of undertreated chronic medical illnesses in patients with severe mental disorders. The Journal of Clinical Psychiatry. 2009;70(Suppl):322-329
  121. 121. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). European Psychiatry. 2009;24:412-424
  122. 122. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychological Medicine. 1999;29:697-701

Written By

Aborlo Kennedy Nkporbu

Submitted: 17 October 2018 Reviewed: 04 December 2019 Published: 06 April 2020